GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (FRA:B00) » Definitions » Cyclically Adjusted Book per Share

Biocept (FRA:B00) Cyclically Adjusted Book per Share : €14,781.10 (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Biocept Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biocept's adjusted book value per share for the three months ended in Jun. 2023 was €0.111. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €14,781.10 for the trailing ten years ended in Jun. 2023.

During the past 12 months, Biocept's average Cyclically Adjusted Book Growth Rate was -7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-31), Biocept's current stock price is €6.80. Biocept's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was €14,781.10. Biocept's Cyclically Adjusted PB Ratio of today is 0.00.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Biocept was 0.04. The lowest was 0.01. And the median was 0.01.


Biocept Cyclically Adjusted Book per Share Historical Data

The historical data trend for Biocept's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Cyclically Adjusted Book per Share Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 2,401.17 2,202.20

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,711.93 2,750.81 2,202.20 2,336.64 14,781.10

Competitive Comparison of Biocept's Cyclically Adjusted Book per Share

For the Diagnostics & Research subindustry, Biocept's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocept's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biocept's Cyclically Adjusted PB Ratio falls into.



Biocept Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biocept's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book= Book Value per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.111/128.7287*128.7287
=0.111

Current CPI (Jun. 2023) = 128.7287.

Biocept Quarterly Data

Book Value per Share CPI Adj_Book
201309 -15,452.941 98.790 -20,136.016
201312 -53,517.647 98.326 -70,065.538
201403 42,281.250 99.695 54,594.891
201406 31,662.500 100.560 40,531.948
201409 16,225.000 100.428 20,797.261
201412 -1,118.750 99.070 -1,453.676
201503 19,016.667 99.621 24,573.015
201506 14,269.565 100.684 18,244.253
201509 8,818.571 100.392 11,307.762
201512 4,643.836 99.792 5,990.386
201603 -593.243 100.470 -760.098
201606 -405.435 101.688 -513.247
201609 -4,364.516 101.861 -5,515.737
201612 322.165 101.863 407.135
201703 3,290.878 102.862 4,118.427
201706 2,048.276 103.349 2,551.274
201709 1,005.357 104.136 1,242.786
201712 280.051 104.011 346.603
201803 912.698 105.290 1,115.880
201806 284.363 106.317 344.308
201809 583.841 106.507 705.656
201812 173.364 105.998 210.541
201903 197.201 107.251 236.693
201906 151.101 108.070 179.986
201909 91.177 108.329 108.346
201912 55.250 108.420 65.599
202003 56.770 108.902 67.106
202006 52.959 108.767 62.678
202009 40.598 109.815 47.590
202012 43.610 109.897 51.083
202103 50.337 111.754 57.983
202106 51.071 114.631 57.352
202109 61.278 115.734 68.158
202112 59.057 117.630 64.629
202203 59.861 121.301 63.527
202206 54.428 125.017 56.044
202209 48.877 125.227 50.244
202212 14.699 125.222 15.111
202303 3.826 127.348 3.867
202306 0.111 128.729 0.111

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Biocept  (FRA:B00) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biocept's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=6.80/14781.1
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Biocept was 0.04. The lowest was 0.01. And the median was 0.01.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biocept Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Biocept's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocept (FRA:B00) Business Description

Traded in Other Exchanges
Address
9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept (FRA:B00) Headlines

No Headlines